Investor Presentaiton

Top-tier talent Differentiated process Scalable platform Adding unmatched portfolio breadth over the last two years 21 products - 25 diseases (1) Inflammatory bowel disease Entyvio Takeda Approved Infectious disease PREVYMIS MERCK Hereditary angioedema orladeyo (3) bio cryst AML, MDS Migraine Cystic fibrosis IDHIFA Bristol Myers Squibb™ Nurtec'ODT biohaven trikafta ☐ pharmaceuticals VERTEX Pre-approval Roche Evrysdi 2020 biohaven ☐ pharmaceuticals SMA zavegepant Type 1 hyperoxaluria OXLUMO Solid tumors 2 Alnylam PsO, PsA, IBD CABOMETYX® EXELIXIS Takeda IPSEN Johnson & Johnson seltorexant Depression Tremfya Johnson & Johnson 2021 Roche gsk otilimab RA Hereditary angioedema orladeyo (3) bio cryst Constellati n PHARMACEUTICALS bio cryst (3) BCX9930 PNH, others Migraine bio cryst (3) BCX9930 PNH, others gantenerumab Alzheimer's CPI-0209 Liquid tumors AML: acute myeloid leukemia; MDS: myelodysplastic syndromes; PSO: plaque psoriasis; PSA; psoriatic arthritis; IBD: inflammatory bowel disease; SMA: spinal muscular atrophy; PNH: paroxysmal nocturnal hemoglobinuria; RA: rheumatoid arthritis pelabresib Myelofibrosis ROYALTY PHARMA 1. Includes January 2022 aficamten royalty acquisition, which is not shown here. 2. Other products included in cystic fibrosis deal not shown include Symdeko, Orkambi and Kalydeco. 3. Purchase of incremental royalties on Orladeyo and BCX9930 in November 2021 is not included in product/disease total. 40 67

View entire presentation